Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $6.00

Taysha Gene Therapies (NASDAQ:TSHA) had its price target upped by JMP Securities from $5.00 to $6.00 in a research note published on Thursday,Benzinga reports. They currently have a market outperform rating on the stock.

Several other research firms have also weighed in on TSHA. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, May 16th. Chardan Capital upped their price target on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research note on Thursday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus target price of $7.00.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $2.71 on Thursday. The stock’s fifty day moving average is $1.92 and its two-hundred day moving average is $1.90. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The firm has a market capitalization of $581.73 million, a P/E ratio of 4.30 and a beta of 0.90. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same quarter in the previous year, the company posted ($0.10) EPS. On average, research analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its stake in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after acquiring an additional 11,390 shares in the last quarter. LPL Financial LLC acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $104,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $8,650,000. Hsbc Holdings PLC lifted its position in shares of Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after purchasing an additional 8,076 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Taysha Gene Therapies by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock worth $15,409,000 after purchasing an additional 641,305 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.